An independent appraisal committee voted that evidence is not adequate to demonstrate a superior net health benefit for ublituximab when compared to other monoclonal antibodies. Analyses suggest ublituximab and all currently available monoclonal antibodies labeled for MS would achieve common thresholds for cost-effectiveness if priced between $16,500- $34,900 per year, a range far lower than […]
Given current data, trilaciclib would achieve common thresholds for cost effectiveness if priced between $430-670 per vial; plinabulin would achieve common thresholds for cost effectiveness if priced between $1,100 - $1,600 per dose.
What Is In The Final Evidence Report? The full report includes a summary of the public meeting discussion, and any necessary updates to ICER’s conclusions following those discussions. When Is The Final Evidence Report Released? Around three weeks after the public meeting. What is the ICER Snapshot? The Snapshot is a patient-friendly summary of ICER’s […]
The Institute for Clinical and Economic Review (ICER) conducted a systematic literature review and cost-effectiveness analysis to evaluate the health and economic outcomes of these TIMs for UC. The clinical evidence shows that TIMs are superior to conventional therapy alone. Results supported by the single head-to-head trial and indirect treatment comparison suggests that vedolizumab had […]
Interventions of Interest: JAK- Inhibitors Baricitinib (Olumiant®, Eli Lilly and Co.) Tofacitinib (Xeljanz®, Pfizer) Upadacitinib (Rinvoq™, AbbVie) adalimumab (Humira®, AbbVie) Rheumatoid arthritis (RA) is the most common autoimmune inflammatory arthritis in adults, affecting approximately 1.5 million Americans. RA is more common in women and may occur at any age, with peak incidence occurring at ages […]
Updating Assessments ICER recognizes that relevant new data may become available after we complete an initial evidence report. We have established the following processes to update our assessments. 12-Month Report Check-Up Because our reports are designed to coincide with the FDA approval timeline, we recognize that available information is always changing, we offer stakeholders this […]
Considering Clinical, Real-World, and Unpublished Evidence Comparative clinical effectiveness involves weighing the benefits and harms/burdens of one treatment option versus another. The most important benefits and harms are those that are important to patients and their families/caregivers. As such, from the outset of a review ICER solicits input from patients, families, caregivers, and expert clinicians […]
In the United States, consequential decisions around prescription drug pricing and patient access are generally made based on limited evidence and without patients in the room.
By Steve Pearson(This commentary is being co-posted by The Donaghue Foundation) In the United States, consequential decisions around prescription drug pricing and patient access are generally made based on limited evidence and without patients in the room. In confidential negotiations, drugmakers and insurers make financial tradeoffs that seriously affect the health and wealth of all Americans. […]
— ICER’s ongoing assessment emphasizes that policymakers will need to consider, in addition to traditional measures of clinical effectiveness and cost-effectiveness, that new interventions for sickle cell disease will differentially benefit an historically disadvantaged and underserved community — — Public comment period now open until February 20, 2020; Requests to make oral comment during public […]